Literature DB >> 16758201

[Radionuclide bone scan in patients with newly diagnosed prostate cancer. Clinical aspects and cost analysis].

T Klatte1, D Klatte, M Böhm, E P Allhoff.   

Abstract

BACKGROUND: The indication for a radionuclide bone scan in patients with newly diagnosed, untreated prostate cancer remains controversial. PATIENTS AND METHODS: In this retrospective study we examined 406 patients who had received a staging bone scan irrespective of their PSA serum level and histology. We evaluated different guidelines and recommendations with respect to their usefulness. The costs were calculated according to EBM and GOA. We evaluated the classification systems of bone metastases according to Soloway, Crawford, and Rigaud.
RESULTS: The bone scan was positive in 41 (10%) of 406 patients. The EAU guidelines turned out to be useful with respect to both clinical value and cost efficiency. The Rigaud classification of bone metastases predicted outcome better than the Soloway or Crawford classification.
CONCLUSIONS: The EAU guidelines from 2005 are a useful tool to decide whether to perform a bone scan in patients with newly diagnosed, untreated prostate cancer. A bone scan should be performed if PSA levels exceed 20 ng/ml in patients with a G1/G2 histology, and in patients with G3 histology and locally advanced disease irrespective of PSA level. Bone scan metastases should be classified according to Rigaud.

Entities:  

Mesh:

Year:  2006        PMID: 16758201     DOI: 10.1007/s00120-006-1078-7

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  32 in total

Review 1.  Mechanisms of bone metastasis.

Authors:  G David Roodman
Journal:  N Engl J Med       Date:  2004-04-15       Impact factor: 91.245

2.  THE FUNCTION OF THE VERTEBRAL VEINS AND THEIR ROLE IN THE SPREAD OF METASTASES.

Authors:  O V Batson
Journal:  Ann Surg       Date:  1940-07       Impact factor: 12.969

3.  Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan.

Authors:  M S Soloway; S W Hardeman; D Hickey; J Raymond; B Todd; S Soloway; M Moinuddin
Journal:  Cancer       Date:  1988-01-01       Impact factor: 6.860

Review 4.  EAU guidelines on prostate cancer.

Authors:  G Aus; C C Abbou; M Bolla; A Heidenreich; H-P Schmid; H van Poppel; J Wolff; F Zattoni
Journal:  Eur Urol       Date:  2005-10       Impact factor: 20.096

5.  Cancer statistics, 2005.

Authors:  Ahmedin Jemal; Taylor Murray; Elizabeth Ward; Alicia Samuels; Ram C Tiwari; Asma Ghafoor; Eric J Feuer; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2005 Jan-Feb       Impact factor: 508.702

6.  The value of a baseline bone scan in patients with newly diagnosed prostate cancer.

Authors:  K Lin; Z Szabo; B B Chin; A C Civelek
Journal:  Clin Nucl Med       Date:  1999-08       Impact factor: 7.794

7.  Which patients with prostatic carcinoma require a staging bone scan?

Authors:  P M Kemp; G A Maguire; N J Bird
Journal:  Br J Urol       Date:  1997-04

8.  Prostate Cancer Clinical Guidelines Panel Summary report on the management of clinically localized prostate cancer. The American Urological Association.

Authors:  R G Middleton; I M Thompson; M S Austenfeld; W H Cooner; R J Correa; R P Gibbons; H C Miller; J E Oesterling; M I Resnick; S R Smalley
Journal:  J Urol       Date:  1995-12       Impact factor: 7.450

9.  Extent of disease based on initial bone scan: important prognostic predictor for patients with metastatic prostatic cancer. Experience from the Scandinavian Prostatic Cancer Group Study No. 2 (SPCG-2).

Authors:  T Jørgensen; C Müller; O Kaalhus; H E Danielsen; K J Tveter
Journal:  Eur Urol       Date:  1995       Impact factor: 20.096

10.  The role of increasing detection in the rising incidence of prostate cancer.

Authors:  A L Potosky; B A Miller; P C Albertsen; B S Kramer
Journal:  JAMA       Date:  1995-02-15       Impact factor: 56.272

View more
  1 in total

1.  Is ¹⁵³Samarium-ethylene-diamine-tetramethyl-phosphonate (EDTMP) bone uptake influenced by bisphosphonates in patients with castration-resistant prostate cancer?

Authors:  Matthias Waldert; Tobias Klatte; Mesut Remzi; Helmut Sinzinger; Christian Kratzik
Journal:  World J Urol       Date:  2011-05-11       Impact factor: 4.226

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.